PUBLISHER: The Business Research Company | PRODUCT CODE: 1957614
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957614
Pharma grade calcium sulphate is a refined form of calcium sulphate (CaSO4) that is specially manufactured and tested to comply with strict pharmaceutical quality standards for use in medicines and healthcare applications. It is commonly utilized as a diluent or excipient in tablets and capsules because of its high purity, controlled particle size, and non-toxic properties.
The primary types of pharma grade calcium sulphate include calcium sulphate dihydrate (CaSO4*2H2O), calcium sulphate hemihydrate, and calcium sulphate anhydrite. Calcium sulphate dihydrate is a pharmaceutical-grade excipient employed as a binder, carrier, and controlled-release agent in drug formulations. Pharma grade calcium sulphate is applied across various uses such as pharmaceutical excipients, tablet binders, calcium supplements, and diagnostic agents. It is distributed through multiple channels, including direct distribution, online distribution, wholesale distribution, and retail distribution.
Tariffs have affected the pharma grade calcium sulphate market by increasing the cost of imported raw materials and specialized processing equipment used in excipient manufacturing. These impacts are most evident in pharmaceutical excipient production hubs across Asia Pacific and Europe, where reliance on cross border sourcing remains high. Rising tariff related expenses have raised overall production costs and influenced pricing strategies for excipient suppliers. This has affected procurement planning for pharmaceutical formulators and contract manufacturers. However, tariffs have encouraged domestic excipient production, expanded local processing capacity, and strengthened regional supply chains over the long term.
The pharma grade calcium sulphate market research report is one of a series of new reports from The Business Research Company that provides pharma grade calcium sulphate market statistics, including pharma grade calcium sulphate industry global market size, regional shares, competitors with a pharma grade calcium sulphate market share, detailed pharma grade calcium sulphate market segments, market trends and opportunities, and any further data you may need to thrive in the pharma grade calcium sulphate industry. This pharma grade calcium sulphate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharma grade calcium sulphate market size has grown strongly in recent years. It will grow from $0.96 billion in 2025 to $1.04 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to growth in pharmaceutical manufacturing, increased demand for solid dosage forms, expansion of generic drug production, rising use of calcium-based excipients, regulatory emphasis on excipient quality.
The pharma grade calcium sulphate market size is expected to see strong growth in the next few years. It will grow to $1.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growth in global drug production, increasing use of high-performance excipients, rising demand for consistent formulation quality, expansion of nutraceutical manufacturing, advancements in excipient processing. Major trends in the forecast period include increasing demand for high-purity pharmaceutical excipients, growing use in tablet and capsule formulations, rising adoption in calcium supplement manufacturing, expansion of quality-controlled excipient production, increasing focus on regulatory-compliant materials.
The increasing demand for pharmaceuticals is projected to drive the growth of the pharma grade calcium sulphate market in the coming years. Pharmaceuticals are drugs and medicinal products developed, manufactured, and used to diagnose, treat, or prevent diseases in humans and animals. The rising demand for pharmaceuticals is largely attributed to the growing prevalence of chronic conditions, as a greater number of patients require long-term therapies to manage diseases such as diabetes, cardiovascular disorders, and cancer. Pharma grade calcium sulphate improves pharmaceutical formulations by functioning as a high-purity excipient that delivers uniform tablet hardness, stability, and controlled release of active ingredients. For example, in April 2024, data from Eurostat, a Luxembourg-based official statistical agency of the European Union, indicated that imports of medicinal and pharmaceutical products into the EU increased by 6.1% in 2023, reaching $137.4 billion (€119 billion) compared with the previous year. During the same period, EU exports amounted to $319.2 billion (€277 billion), resulting in a trade surplus of $182.0 billion (€158 billion). Consequently, the growing demand for pharmaceuticals is contributing to the expansion of the pharma grade calcium sulphate market.
Major companies operating in the pharma grade calcium sulphate market are concentrating on developing innovative products through the use of synthetic medical-grade bassanite to improve the purity and consistency of calcium sulphate offerings. Synthetic medical-grade bassanite is a high-purity, partially dehydrated form of calcium sulphate (CaSO4*0.5H2O) that enables the production of pharma-grade calcium sulphate by providing a uniform, contaminant-free raw material that complies with stringent regulatory requirements for medical and pharmaceutical use. For instance, in February 2025, the Sree Chitra Tirunal Institute for Medical Sciences & Technology, an India-based medical institute, introduced Caspro and Bonyx, advanced drug-eluting bone graft products developed using synthetic medical-grade bassanite to ensure high purity, biocompatibility, and controlled drug release for orthopedic applications. Caspro is a self-setting, mouldable bone cement composed of calcium sulfate hemihydrate reinforced with phosphate ions, designed for filling bone defects and delivering drugs at the implantation site for more than 21 days. Bonyx comprises osteoconductive bioceramic beads that can be vacuum-loaded with antibiotics or other liquid medications, allowing sustained drug release for over 30 days. These products highlight advancements in localized therapy for bone infections and regeneration, demonstrating the application of pharma-grade calcium sulphate in next-generation biomedical solutions that meet strict international standards.
In July 2024, Sudeep Pharma Pvt. Ltd., an India-based pharmaceutical company, acquired a 50% stake in JRS Pharma GmbH + Co. KG for an undisclosed amount. Through this acquisition, Sudeep Pharma aims to reinforce its market leadership, accelerate innovation, and expand its presence in emerging pharmaceutical and nutraceutical markets. JRS Pharma GmbH + Co. KG is a Germany-based pharmaceutical company that produces a pharmaceutical-grade calcium sulphate product known as Compactrol.
Major companies operating in the pharma grade calcium sulphate market are Thermo Fisher Scientific Inc., Merck KGaA, Honeywell International Inc., Avantor Inc., Spectrum Chemical Manufacturing Corp., MP Biomedicals LLC, Anhui Sunhere Pharmaceutical Excipients, Huzhou Zhanwang Pharmaceutical Co. Ltd., Loba Chemie Pvt. Ltd., SRL Chemical, GFS Chemicals Inc., American Elements, Junsei Chemical Co. Ltd., Tokyo Chemical Industry Co. Ltd., Fagron N.V., Mallinckrodt Pharmaceuticals, Ashland Global Holdings Inc., JRS Pharma, DFE Pharma, Roquette Freres
North America was the largest region in the pharma grade calcium sulphate market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharma grade calcium sulphate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pharma grade calcium sulphate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pharma grade calcium sulphate market consists of sales of USP-grade calcium sulfate dihydrate, anhydrous calcium sulfate, calcium sulfate hemihydrate (medical grade plaster of paris), injectable calcium sulfate pellets, and food or nutraceutical grade calcium sulfate. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharma Grade Calcium Sulphate Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pharma grade calcium sulphate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pharma grade calcium sulphate ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharma grade calcium sulphate market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.